For more information about product candidates, visit this page on the company's website. One always hopes that health can win the war over disease, and Human Genome Sciences may have everything in place to help it win at least many battles over the years. However, the risks for investors are high. The company has low revenue numbers and is burning cash on research and development for new product candidates. And that assumes that most all things go well.
Drug development is a complex, time consuming business.
This company isn't striving every day to grow revenue, right now, it is aiming toward a product. So, this story isn't a financial one yet. You can find HGS's financial data by clicking here . You need to love science if you're going to love this company. If any of these three things do not make your heart go pitter-patter, then this isn't an investment for you.